395 related articles for article (PubMed ID: 14658923)
21. Approach to common bacterial infections: community-acquired pneumonia.
Iroh Tam PY
Pediatr Clin North Am; 2013 Apr; 60(2):437-53. PubMed ID: 23481110
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
Noreddin AM; El-Khatib WF; Aolie J; Salem AH; Zhanel GG
Int J Infect Dis; 2009 Jul; 13(4):483-7. PubMed ID: 19046911
[TBL] [Abstract][Full Text] [Related]
23. Community-acquired pneumonia in children.
Sinaniotis CA; Sinaniotis AC
Curr Opin Pulm Med; 2005 May; 11(3):218-25. PubMed ID: 15818183
[TBL] [Abstract][Full Text] [Related]
24. Evolution of acute infection with atypical bacteria in a prospective cohort of children with community-acquired pneumonia receiving amoxicillin.
Nascimento-Carvalho CM; Xavier-Souza G; Vilas-Boas AL; Fontoura MH; Barral A; Puolakkainen M; Ruuskanen O;
J Antimicrob Chemother; 2017 Aug; 72(8):2378-2384. PubMed ID: 28475737
[TBL] [Abstract][Full Text] [Related]
25. Community-acquired pneumonia in children.
Stuckey-Schrock K; Hayes BL; George CM
Am Fam Physician; 2012 Oct; 86(7):661-7. PubMed ID: 23062094
[TBL] [Abstract][Full Text] [Related]
26. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
Vergis EN; Indorf A; File TM; Phillips J; Bates J; Tan J; Sarosi GA; Grayston JT; Summersgill J; YU VL
Arch Intern Med; 2000 May; 160(9):1294-300. PubMed ID: 10809032
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of the efficiency of antimicrobial treatment for community-acquired pneumonia in clinical practice].
Zhukova OV; Ruina OV; Kononova SV; Konyshkina TM
Ter Arkh; 2017; 89(8):17-21. PubMed ID: 28914846
[TBL] [Abstract][Full Text] [Related]
28. Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia.
Esposito S; Bianchini S; Gambino M; Madini B; Di Pietro G; Umbrello G; Presicce ML; Ruggiero L; Terranova L; Principi N
BMC Pulm Med; 2016 Jul; 16(1):103. PubMed ID: 27439403
[TBL] [Abstract][Full Text] [Related]
29. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia.
Lui G; Ip M; Lee N; Rainer TH; Man SY; Cockram CS; Antonio GE; Ng MH; Chan MH; Chau SS; Mak P; Chan PK; Ahuja AT; Sung JJ; Hui DS
Respirology; 2009 Nov; 14(8):1098-105. PubMed ID: 19818051
[TBL] [Abstract][Full Text] [Related]
30. [Recommendation of the Brazilian Society of Pediatrics for antibiotic therapy in children and adolescents with community-acquired pneumonia].
Nascimento-Carvalho CM; Souza-Marques HH
Rev Panam Salud Publica; 2004 Jun; 15(6):380-7. PubMed ID: 15272984
[TBL] [Abstract][Full Text] [Related]
31. Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children.
Tajima T; Nakayama E; Kondo Y; Hirai F; Ito H; Iitsuka T; Momomura M; Kutsuma H; Kodaka Y; Funaki N; Yanagawa Y; Ubukata K
J Infect Chemother; 2006 Dec; 12(6):372-9. PubMed ID: 17235643
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options for pneumococcal pneumonia in Turkey.
Oncu S; Erdem H; Pahsa A
Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
[TBL] [Abstract][Full Text] [Related]
33. [Community-acquired pneumonia in children].
Gendrel D; Moulin F
Rev Prat; 2007 Nov; 57(17):1883-94. PubMed ID: 18095624
[TBL] [Abstract][Full Text] [Related]
34. Improving outcomes of elderly patients with community-acquired pneumonia.
Gutiérrez F; Masiá M
Drugs Aging; 2008; 25(7):585-610. PubMed ID: 18582147
[TBL] [Abstract][Full Text] [Related]
35. Management of community-acquired pneumonia in children.
Chetty K; Thomson AH
Paediatr Drugs; 2007; 9(6):401-11. PubMed ID: 18052410
[TBL] [Abstract][Full Text] [Related]
36. [Clinical efficacy of oral clarithromycin monotherapy in patients with mild or moderate community-acquired pneumonia].
Fujiki R; Rikimaru T; Aizawa H; Kawayama T
Jpn J Antibiot; 2003 Dec; 56(6):712-8. PubMed ID: 15007880
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.
Plouffe J; Schwartz DB; Kolokathis A; Sherman BW; Arnow PM; Gezon JA; Suh B; Anzuetto A; Greenberg RN; Niederman M; Paladino JA; Ramirez JA; Inverso J; Knirsch CA
Antimicrob Agents Chemother; 2000 Jul; 44(7):1796-802. PubMed ID: 10858333
[TBL] [Abstract][Full Text] [Related]
38. The incidence and etiology of community-acquired pneumonia in fever outpatients.
Bao Z; Yuan X; Wang L; Sun Y; Dong X
Exp Biol Med (Maywood); 2012 Nov; 237(11):1256-61. PubMed ID: 23239436
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of new antibacterial therapies in at-risk populations.
Lorenz J
J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
[TBL] [Abstract][Full Text] [Related]
40. The emerging role of atypical pathogens in community-acquired pneumonia.
Gleason PP
Pharmacotherapy; 2002 Jan; 22(1 Pt 2):2S-11S; discussion 30S-32S. PubMed ID: 11791627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
